MIF

Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research

Retrieved on: 
Tuesday, March 29, 2022
Technology, Biotechnology, Health, Pharmaceutical, Oncology, Other Technology, Research, Medical Devices, Software, Managed Care, Hospitals, Science, Clinical Trials, Cardiology, Biomarker, MIF, Eye, Patient, Cros, Tumor microenvironment, Research, Pathology, Noise, Precision medicine, CEO, Marie Cassidy, Industry, Technology, Spatial analysis, Doctor of Philosophy, Deep learning, CRO, Solution, AI, Partnership, Medical imaging, Fine chemical, KEEN EYE, ULTIVUE

Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.

Key Points: 
  • Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
  • This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
  • Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis.
  • Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms.

Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine

Retrieved on: 
Tuesday, March 15, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CRO, Solution, Proteomics, Genomics, Immunotherapy, Doctor of Philosophy, Drug discovery, Partnership, Corporate development, Research, Drug development, MIF, Industry, Precision medicine, Workflow, Pathology, Medical imaging, Fine chemical, Sutro Biopharma, Sirona Dx, Ultivue, SIRONA DX, ULTIVUE

Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.

Key Points: 
  • Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.
  • Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018.
  • We are delighted to announce this partnership with Ultivue said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Ultivue Announces Co-Marketing Agreement with Aignostics for Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

Retrieved on: 
Wednesday, March 9, 2022
Software, Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Genetics, Science, Biotechnology, Other Science, Health, Industry, Clinical trial, Pathology, Partnership, Research, Workflow, Artificial intelligence, Precision medicine, IHC, H&E, GCP, Solution, Technology, Cdx, MIF, CEO, Algorithm, NSCLC, Medical imaging, Pharmaceutical industry, Sutro Biopharma, Technical University of Berlin, Ultivue, Aignostics, ULTIVUE, AIGNOSTICS

These results will be published later this year and respective AI models made available via the platform.

Key Points: 
  • These results will be published later this year and respective AI models made available via the platform.
  • We are excited to start offering this approach to our clients for translational science and clinical trials, said Viktor Matyas, CEO of Aignostics.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.
  • These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

Retrieved on: 
Tuesday, February 22, 2022
CIPN, Risk, GLOBE, Chemotherapy-induced peripheral neuropathy, Substance dependence, Lists of diseases, Annual report, Pharmacology, Population, Intellectual property, Nasdaq, Code, IPF, Failure, Tokyo Stock Exchange, MPH, NASDAQ, Security (finance), Grammatical mood, University, Psychology, DCM, Glioblastoma, Private Securities Litigation Reform Act, Disease, Amyotrophic lateral sclerosis, AUD, Multiple sclerosis, U.S. Securities and Exchange Commission, Disorder, MS, Acute respiratory distress syndrome, ALS, Neuroinflammation, NIAAA, Neurodegeneration, MIF, Fatty liver disease, FDA, Brain, Patient, Form 8-K, University of California, San Francisco Fetal Treatment Center, NASH, PDE4, Drug, Form 10-K, Psychiatry, MD, Idiopathic pulmonary fibrosis, Naltrexone, Department, Pharmaceutical industry, Doctor of Philosophy

Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with limited treatment options.

Key Points: 
  • Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with limited treatment options.
  • AUD is a chronic relapsing brain disease characterized by compulsive alcohol use, loss of control over alcohol intake, and a negative emotional state when not using alcohol.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Gilbane | Exyte Joint Venture Awarded Contract to Construct $279 Million Advanced Semiconductor Facility for MIT LL at Hanscom Air Force Base

Retrieved on: 
Wednesday, February 9, 2022
Exyte, Government, Defense, Department, Growth, Ministry of Education (Malaysia), Hanscom Air Force Base, Massachusetts Institute of Technology, U.S. Army Corps of Engineers, Europe District, Technology, Corps, Federally funded research and development centers, CSL, MIT Lincoln Laboratory, Engineer, Georgia Department of Defense, MIF, Gilbane, Inc., MIT, Partnership, Danto Engineering Development Center, AFB

BOSTON, Feb. 9, 2022 /PRNewswire-PRWeb/ --Gilbane, in a joint venture partnership with leading cleanroom constructor Exyte, has been awarded the Firm Fixed Price construction of a new a $279 million Advanced Compound Semiconductor Laboratory/Microsystem Integration Facility (CSL-MIF) for the Massachusetts Institute of Technology Lincoln Laboratory (MIT LL) located at Hanscom Air Force Base (AFB) in Massachusetts.

Key Points: 
  • BOSTON, Feb. 9, 2022 /PRNewswire-PRWeb/ --Gilbane, in a joint venture partnership with leading cleanroom constructor Exyte, has been awarded the Firm Fixed Price construction of a new a $279 million Advanced Compound Semiconductor Laboratory/Microsystem Integration Facility (CSL-MIF) for the Massachusetts Institute of Technology Lincoln Laboratory (MIT LL) located at Hanscom Air Force Base (AFB) in Massachusetts.
  • "In order to deliver the best value to the government, Gilbane formed a JV with Exyte - the premier, leading-edge microelectronics facility construction firm.
  • MIT LL is a Federally Funded Research and Development Center chartered to apply advanced technology to problems of national security.
  • The new MIF will consolidate and enhance MIT LL's facilities for the fabrication and packaging of specialized advanced electronic prototypes.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

Retrieved on: 
Monday, December 13, 2021
Tokyo Stock Exchange, Tablet, Failure, Neurodegeneration, Life expectancy, U.S. Securities and Exchange Commission, FDA, Intellectual property, Idiopathic pulmonary fibrosis, Fatty liver disease, ALS, Nasdaq, Riluzole, MS, Brain, Private Securities Litigation Reform Act, Spinal cord, NASH, Multiple sclerosis, Chemotherapy-induced peripheral neuropathy, CIPN, MPH, DCM, NASDAQ, Risk, Annual report, Form 10-K, Association, Capsule, Patient, Disease, IPF, Security (finance), Patent, Substance dependence, Form 8-K, MD, Glioblastoma, GLOBE, Amyotrophic lateral sclerosis, Muscle, Code, PDE4, ALS Association, MIF, Pharmaceutical industry, Doctor of Philosophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanNovember 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanNovember 2035.
  • Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer ofMediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted.
  • Once this new patent is granted, we will have three different U.S. patents that cover MN-166 for the treatment of ALS.
  • We believe it could substantially increase the potential value of MN-166 as it further strengthens our patent portfolio for ALS.

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

Retrieved on: 
Wednesday, November 17, 2021
GMP, Cancer, MIF, CDMO, Immortalised cell line, CEO, Partnership, Company, Solution, Therapy, Drug discovery, GenScript Biotech, Lung, Patient, FDA, Drug development, Neutralizing antibody, Pharmaceutical industry, Vaccine

The companies will combine their respective expertise in drug discovery and manufacturing to bring the resulting mAb candidates into the clinic.

Key Points: 
  • The companies will combine their respective expertise in drug discovery and manufacturing to bring the resulting mAb candidates into the clinic.
  • OxMIF contributes to immune evasive and immune tolerant phenotypes in cancer and is characterizedby its presence in diseased tissue.
  • "It is our pleasure to offer our superior manufacturing services to support the development and manufacturing of this innovative mAbs project," said Dr.Brian Min, CEO of GenScript ProBio.
  • OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumorspecificity of the diseaserelated isoform, oxidized macrophage migration inhibitory factor (oxMIF).

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Wednesday, November 3, 2021
Form 8-K, PDE4, Idiopathic pulmonary fibrosis, Fatty liver disease, Annual report, Neurodegeneration, Failure, MIF, Code, Security (finance), Substance dependence, U.S. Securities and Exchange Commission, Patient, NASDAQ, Private Securities Litigation Reform Act, FDA, Society, CIPN, Multiple sclerosis, SNO, Acute respiratory distress syndrome, MS, Chemotherapy-induced peripheral neuropathy, Risk, Tokyo Stock Exchange, Medicine, Cleveland Clinic, Glioblastoma, Amyotrophic lateral sclerosis, Form 10-K, IPF, DCM, NASH, Research, Intellectual property, GLOBE, ALS, Nasdaq, Pharmaceutical industry

In addition, MN-166 (ibudilast) is being evaluated in patients at risk for developing acute respiratory distress syndrome (ARDS).

Key Points: 
  • In addition, MN-166 (ibudilast) is being evaluated in patients at risk for developing acute respiratory distress syndrome (ARDS).
  • MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
  • Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development.
  • These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029.

Global Irrigation Machinery Market 2021-2026 | A $6.6+ Billion Opportunity Assessment by Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, October 1, 2021
Agriculture, Natural Resources, Other Manufacturing, Manufacturing, Lists of countries and territories, Toro (company), USD, Indian government response to the COVID-19 pandemic, Farmer, Bang Wua, Groundwater, Agriculture, CAGR, Water, Sindicato de Médicos de Asistencia Pública v Conselleria de Sanidad y Consumo de la Generalidad Valenciana, MIF, Government, Ministry of Agriculture, Irrigation and Livestock, Statistics Canada, Growth, Sorghum, NABARD, USDA, COVID-19, Microcredit, Rural development, Canada, National bank

The impact of the COVID-19 pandemic was felt on various businesses including the global irrigation systems market.

Key Points: 
  • The impact of the COVID-19 pandemic was felt on various businesses including the global irrigation systems market.
  • Manufacturing industries were closed due to restrictions aimed at containing COVID-19, which in turn, affected the availability of agricultural inputs and operations of hiring agricultural machinery service providers
    Sprinkler irrigation machinery is the largest segment in the global irrigation machinery market.
  • Also, the market for irrigation machinery is anticipated to grow with increased scarcity of natural irrigation systems and enhanced demand for crop productivity.
  • The global irrigation machinery market is consolidated, with major players occupying only major share of the market studied and other accounting for less share.

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

Retrieved on: 
Monday, August 30, 2021
Badminton Association of India, Tokyo Stock Exchange, Amyotrophic lateral sclerosis, Neurodegeneration, Nasdaq, Private Securities Litigation Reform Act, ALS, MS, Annual report, International Symposium on Graph Drawing, MIF, Quality of life, Observation, Glioblastoma, PDE4, U.S. Securities and Exchange Commission, Life expectancy, Trial of the century, Acute respiratory distress syndrome, GLOBE, Muscle, IPF, Form 8-K, Disease, Chemotherapy-induced peripheral neuropathy, Death, Intellectual property, ALS Association, Fatty liver disease, DCM, Month, NASDAQ, Substance dependence, Safety, Risk, Failure, Patient, Spinal cord, Idiopathic pulmonary fibrosis, Education, NASH, CIPN, FDA, Brain, Association, Code, Security (finance), Form 10-K, Multiple sclerosis, Pharmaceutical industry

The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update will be given by Kazuko Matsuda, M.D.

Key Points: 
  • The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update will be given by Kazuko Matsuda, M.D.
  • We are very pleased to present ongoing activities from the COMBAT-ALS trial at the 32nd International Symposium on ALS/MND.
  • As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed.
  • According to the ALS Association, there are approximately 16,000 ALS patients in the U.S. and approximately 5,000 people in the U.S. are diagnosed with ALS each year.